Giulio Francolini, Radiation Oncologist at Careggi University Hospital, shared a post on X:
“QoL data from DART trial (SBRT+/- darolutamide in oligorec. pCa).
Global health and most QoL subdomains remained stable in both arms over the 24-week period.
More fatigue and hormonal treatment-related symptoms were observed in the SBRT and DARO arm, ESTRO.”
The post presents updated findings from the DART trial, indicating stable quality of life across both study arms over 24 weeks.
However, patients receiving both SBRT and darolutamide experienced increased fatigue and hormonal symptoms.
Stay tuned to OncoDaily for continued coverage and updates from ESTRO25.